Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice
International Journal of Immunopathology and Pharmacology · 2024-01 · 38
DOI: 10.1177/03946320241260262 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, online erschienen am 14.06.2024. Verfasst von Ling Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Psoriasis, Imiquimod, Naphthoquinones, Drug Therapy, Combination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
TYK2 inhibitors and traditional natural drugs as promising drugs for psoriasis therapy are receiving increasing attention. They both affect different molecules of JAK/STAT pathway, but it is currently unclear whether their combination will enhance the effect on psoriasis. In this study, we used imiquimod (IMQ)-induced psoriasis mouse model to investigate the therapeutic effects of the combined administration of deucravacitinib (TYK2 inhibitor) and shikonin.
Methods
Aldara cream containing 5% IMQ was used to topically treat the dorsal skin of each mouse for a total of six consecutive days to induce psoriasis. The psoriasis area and severity index (PASI) scores were recorded every day. On the 7 th day, skin tissues were taken for histopathological examination and the content of cytokines in skin were evaluated. The frequency of immune cells in peripheral blood, spleen and skin were detected through flow cytometry.
Results
Compared to the vehicle control group, the psoriasis symptoms and immune disorder improved significantly in the combination therapy group and deucravacitinib treatment group on the 7th day, and the expressions of p-STAT3 and Ki67 in skin were reduced as well. Moreover, the combined treatment of deucravacitinib and shikonin for psoriasis was superior to the monotherapy group, especially in inhibiting abnormal capillaries proliferation, reducing immune cells infiltration and decreasing the concentration of IL-12p70 in skin.
Conclusion
The combination of deucravacitinib and shikonin is a promising clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nantong University, Nantong, China.
- Biomarker Department, Crown Bioscience, Inc, Suzhou, China.
ORCID-Profile: Lin Luo
Zitieren
APA
Xu, L., Jiang, Y., Xu, F., Liu, J., Jiang, Y., Fang, F., & Luo, L. (2024). Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice. International Journal of Immunopathology and Pharmacology, 38. https://doi.org/10.1177/03946320241260262
Vancouver
Xu L, Jiang Y, Xu F, Liu J, Jiang Y, Fang F, et al. Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice. International Journal of Immunopathology and Pharmacology. 2024;38. doi:10.1177/03946320241260262
BibTeX
@article{Xu2024,
author = {Xu, Ling and Jiang, Ying and Xu, Fuping and Liu, Jun and Jiang, Yuhong and Fang, Fang and Luo, Lin},
title = {Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2024},
volume = {38},
doi = {10.1177/03946320241260262}
}
EUVIMED